A new campaign from AbbVie highlights the “full selves” of people with conditions treated by the company’s therapies, in a ...

Johnson & Johnson will spend $2 billion over the next 10 years to operate a 160,000-square-foot manufacturing facility at ...

For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). | For the second time ...

Starting Sept. 1, the U.S. will impose a “Most Favored Nation” (MFN) tariff rate on generic pharmaceuticals sourced from the EU, including their ingredients and chemical precursors, according to a ...

Swoop and iSpot have joined forces to deliver insights into cross-platform ad exposures against specific audiences for healthcare and pharma marketers. | Swoop and iSpot have joined forces to deliver ...

Nucleus RadioPharma, a CDMO that specializes in the burgeoning field of radiopharmaceuticals, named former FDA Commissioner Dr. Stephen Hahn as its chief executive officer.

The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...

As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

Leo reported that sales of eczema treatment Adbry are scaling up in the U.S. The company also made a positive adjustment to its 2025 sales guidance.

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs ...

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

As its lead candidate advances into a late-stage trial, Inhibikase has picked up a commercial leader with plenty of experience in the PAH space.